US FDA seeks to foster new antibacterial drug development with streamlined approach
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a draft guidance document that explores approaches to help streamline development programs for new antibacterial drugs for patients with unmet medical need1.